LAS VEGAS--(BUSINESS WIRE)--CardioVascular BioTherapeutics, Inc. (OTCBB:CVBT) announced today that the U.S. Food and Drug Administration (FDA) has authorized the company’s Phase II Clinical Protocol for its protein drug candidate, human fibroblast growth factor-1 (FGF-1), for the treatment of severe coronary heart disease.
